At the end of April 2021, the most astonishing news broke out in the CKD community. This was the biggest news toward a new treatment for chronic kidney disease in more than 20 years. The US Food and Drug Administration (FDA) approved AstraZeneca’s Farxiga (dapagliflozin) as a treatment for CKD in patients at risk of further progression with and without type-2 diabetes.
During the DAPA-CKD Phase III trial, the oral, once-daily sodium-glucose cotransporter 2 inhibitor revealed a remarkable drop in the risk of worsening of renal function, end-stage kidney disease (ESKD), and risk of cardiovascular or renal death versus placebo in stage 2-4 CKD patients with high urinary albumin excretion.
Farxiga by AstraZeneca was first approved in 2014 to improve glycemic control in adults with type 2 diabetes. During this trial, 4304 patients were randomly given either Farxiga or a placebo. The trial suggested a 39% decline in the risk of declining renal function, cardiovascular death, as compared to a placebo in stage 2 to 4 CKD patients with high urinary albumin excretion.
For more of the latest information on ways to achieve good kidney health, head over to our YouTube Channel